Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

Leukemia
Maria H GilleeceArnon Nagler

Abstract

Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Transplantation Registry studied an AML CR2 cohort characterised by age ≥ 18 years, first allo-HCT 2007-2016, available cytogenetic profile at diagnosis, donors who were matched family, volunteer unrelated with HLA antigen match 10/10 or 9/10 or haplo-identical. The 1879 eligible patients included 1010 (54%) MAC allo-HCT recipients. In patients <50 years (y), two year outcomes for MAC vs RIC allo-HCT were equivalent with leukaemia-free survival (LFS) 54% for each, overall survival (OS), 61% vs 62%, non-relapse mortality (NRM) 18% vs 15% and graft versus host disease relapse-free survival (GRFS) 38% vs 42%. In patients ≥50 y, 2 y outcomes for MAC vs RIC allo-HCT were equivalent for LFS 52% vs 49%, OS 58% vs 55% and GRFS 42.4% vs 36%. However, NRM was significantly inferior after MAC allo-HCT, 27% vs 19% (P = 0.01) despite worse cGVHD after RIC-allo (32% vs 39%). These data support the need for ongoing prospective study ...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jan 1, 1995·Lifetime Data Analysis·P Hougaard
Sep 10, 2002·Transplant Immunology·Jean-Marie TiercyEddy Roosnek
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea BacigalupoMary Horowitz
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boglarka GyurkoczaBrenda M Sandmaier
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
Dec 19, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fotios V MichelisVikas Gupta
Feb 1, 2014·Blood·Robert Peter Gale, Hillard M Lazarus
May 27, 2014·American Society of Clinical Oncology Educational Book·Frederick R Appelbaum
Dec 3, 2014·Best Practice & Research. Clinical Haematology·Mary Eapen
Mar 19, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Chiara CattaneoPeter Dreger
Apr 12, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mohamed L SorrorMarcelo C Pasquini
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M KadiaH Kantarjian
May 10, 2016·Nature Reviews. Disease Primers·Asim KhwajaDavid C Linch
Dec 29, 2016·Current Opinion in Hematology·David A Sallman, Jeffrey E Lancet
Jan 25, 2017·Cancer·Fotios V MichelisUNKNOWN Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaborati
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart L ScottMitchell E Horwitz
Oct 31, 2017·Annals of Hematology·Dan YangYanli Xu
Nov 21, 2017·Best Practice & Research. Clinical Haematology·Richard M Stone
Feb 10, 2018·Oncotarget·Francesco SaraceniUNKNOWN Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT)
Mar 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanNigel H Russell

❮ Previous
Next ❯

Citations

May 26, 2020·American Journal of Hematology·Frédéric BaronMohamad Mohty
May 21, 2021·Frontiers in Immunology·Justin LokeCharles Craddock
Jul 3, 2021·Cancers·Paolo Bernasconi, Oscar Borsani
Oct 2, 2021·Journal of Managed Care & Specialty Pharmacy·Bhavik J PandyaAmer M Zeidan

❮ Previous
Next ❯

Software Mentioned

SPSS
R

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

© 2021 Meta ULC. All rights reserved